Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: An update

被引:34
作者
Yukawa, E [1 ]
Honda, T [1 ]
Ohdo, S [1 ]
Higuchi, S [1 ]
Aoyama, T [1 ]
机构
[1] KYUSHU UNIV HOSP, FAC MED, DEPT HOSP PHARM, HIGASHI KU, FUKUOKA 812, JAPAN
关键词
D O I
10.1002/j.1552-4604.1997.tb04766.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The steady-state concentrations of digoxin at trough levels were studied to reestablish the role of patient characteristics in estimating doses for digoxin using routine therapeutic drug-monitoring data. The data (n = 548) showing steady state serum concentrations of digoxin after repetitive oral administration in 385 hospitalized patients were analyzed using NONMEM, a computer program designed to analyze pharmacokinetics in study populations by allowing pooling of data. Analysis of the pharmacokinetics of digoxin was accomplished with a simple steady-state pharmacokinetic model. The effect of a variety of developmental and demographic factors on the clearance of digoxin was investigated. Estimates generated by NONMEM indicated that clearance of digoxin was influenced by the demographic variables of age, total body weight, serum creatinine, estimated creatinine clearance, gender, the coadministration of spironolactone, the presence or absence of congestive heart failure, and the administration of a half-tablet. The interindividual variability in the clearance of digoxin was modeled with proportion error with an estimated coefficient of variation of similar to 22%; the residual variability was similar to 25.0%. An a priori method, based on the value for clearance of digoxin obtained by NONMEM analysis, was proposed as a useful adjunct for the prediction of the steady-state concentration of digoxin at trough level as a function of the maintenance dose of digoxin.
引用
收藏
页码:92 / 100
页数:9
相关论文
共 25 条
[1]   CLINICAL PHARMACOKINETICS OF DIGOXIN 1980 [J].
ARONSON, JK .
CLINICAL PHARMACOKINETICS, 1980, 5 (02) :137-149
[2]   Mixed-effect modeling for detection and evaluation of drug interactions: Digoxin-quinidine and digoxin-verapamil combinations [J].
Bauer, LA ;
Horn, JR ;
Pettit, H .
THERAPEUTIC DRUG MONITORING, 1996, 18 (01) :46-52
[3]  
BEAL SL, 1992, NONMEM USERS GUIDE
[4]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[5]   SERUM CONCENTRATION MONITORING OF CARDIAC-GLYCOSIDES - HOW HELPFUL IS IT FOR ADJUSTING DOSAGE REGIMENS [J].
DOBBS, RJ ;
ONEILL, CJA ;
DESHMUKH, AA ;
NICHOLSON, PW ;
DOBBS, SM .
CLINICAL PHARMACOKINETICS, 1991, 20 (03) :175-193
[6]   THERAPEUTIC DRUG-MONITORING OF DIGOXIN - HELP OR HINDRANCE [J].
DOBBS, RJ ;
NICHOLSON, PW ;
DENHAM, MJ ;
DOBBS, SM ;
ONEILL, CJA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (04) :491-495
[7]  
FENSTER PE, 1984, CLIN PHARMACOL THER, V36, P70, DOI 10.1038/clpt.1984.141
[8]   INFLUENCE OF SPIRONOLACTONE AND ITS METABOLITE CANRENONE ON SERUM DIGOXIN ASSAYS [J].
FOUKARIDIS, GN .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :82-84
[9]   DIGOXIN-INTERACTIONS IN MAN - SPIRONOLACTONE REDUCES RENAL BUT NOT BILIARY DIGOXIN CLEARANCE [J].
HEDMAN, A ;
ANGELIN, B ;
ARVIDSSON, A ;
DAHLQVIST, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 42 (05) :481-485
[10]  
Hori R, 1994, JPN J THER DRUG MONI, V11, P7